Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, is 1 of 6 cochairs for the 2024 Community Oncology Conference, and here she discusses how meeting content has incorporated ongoing coverage of the extremely disruptive cyberattack and how there is still so much work to be done.
The Change Healthcare cyberattack was a learning moment in that we need to have backup plans and to be able to pivot to continue to deliver high-quality care to our patients, explains Kathy Oubre, MS, CEO of Pontchartrain Cancer Center and a cochair of the Community Oncology Alliance's (COA's) 2024 Community Oncology Conference.
In addition to being 1 of 6 cochairs, Oubre also was a panelist for 2 timely discussions: "The Post-DIR Hangover: Underwater Reimbursement & Challenges" and "Revenue Cycle Management Success in Community Oncology: Measurement & Dashboards."
Transcript
How does meeting content reflect coverage of the Change Healthcare cyberattack?
The way that COA will interweave the Change Healthcare cyberattack into the COA meeting is really just by bringing that conversation in to all of the sessions that we have for this year's meeting, whether that's being more mindful of the current crisis during our cyberattack session or it really also brings to light the relevance of a very successful strong revenue cycle program within the practices. It's not going to really change what we're going to say. But it's going to perhaps bring a greater emphasis to some of the things that we are going to talk about.
Have providers been adequately compensated by payers given the scale of this disruption?
UnitedHealthcare, as well as CMS, did accelerate payments, or loan programs, to providers that requested it. Is that enough funding? I can't speak for all practices. For my practice, yes, I consider it adequate.
But what can the payers do to help us more? I think the payers need to work with practices to bring us back online faster. What do I mean by that? So just because we're doing better or back online, doesn’t mean that my organization can submit electronic claims with all of my payers. My largest commercial payer requires an EDI [electronic data Interchange] application; we are in process. So I still have 8 of my commercial payers that we are still not fully online with.
It's not necessarily, in my perspective, about another loan program at this point. I think it's more about the payers having workarounds or a strategy to bring practices online faster in a more efficient manner so that we can process claims.
What lessons can community oncology take away from how Ponchartrain has pivoted to adjust its operations?
Immediately right after the Change Healthcare cyberattack we were not able to verify benefits or eligibility in an electronic manner. We had to go old school and phone call our payers to confirm all of those things that allow us to deliver appropriate patient care. I think there are a lot of lessons learned there.
I think we have a lot of new staff that perhaps has never done that before. All they’ve known is that electronic way of doing things. Fortunately, we also have some more seasoned professionals within our organization. But it was a learning moment that we all need to be able to have backup plans, disaster plans. When things within our organization—be it something internally or an outside force—if we go down for a reason, we do need to be able to pivot and move in order to continue to deliver high-quality care to our patients.
So perhaps that was pulling some teams, or some people within our organization, who their sole job every day was to make those phone calls to all of our payers to verify eligibility, co-pay assistance, and appropriate co-pays or coinsurance on our patients, prior authorizations to keep our health care system moving.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Insurance Payer Is Associated With Length of Stay After Traumatic Brain Injury
February 21st 2025Among hospitalized patients with traumatic brain injury, Medicaid fee-for-service was associated with longer hospital stays than private insurance and Medicaid managed care organizations.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Insurance Payer Is Associated With Length of Stay After Traumatic Brain Injury
February 21st 2025Among hospitalized patients with traumatic brain injury, Medicaid fee-for-service was associated with longer hospital stays than private insurance and Medicaid managed care organizations.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
2 Commerce Drive
Cranbury, NJ 08512